Introduction:
In recent years, biosimilars have gained significant traction in the pharmaceutical industry, particularly in the field of chemotherapy. As the demand for cost-effective treatment options continues to rise, biosimilars are playing a crucial role in providing affordable alternatives to expensive biologic drugs. In India, the market for biosimilars chemotherapy pairings is expected to grow substantially by 2026. According to industry experts, the production volume of biosimilars in India is projected to increase by 30% over the next five years.
Top 10 Biosimilars Chemotherapy Pairings in India 2026:
1. Rituximab – Trastuzumab
– Market share: 25%
– These two biosimilars are expected to dominate the Indian market due to their efficacy and affordability in treating various types of cancer.
2. Bevacizumab – Pembrolizumab
– Market share: 20%
– The combination of these biosimilars has shown promising results in the treatment of colorectal cancer and is anticipated to see increased adoption in the coming years.
3. Filgrastim – Pegfilgrastim
– Market share: 15%
– These biosimilars are widely used in chemotherapy-induced neutropenia and are projected to maintain a strong presence in the Indian market.
4. Infliximab – Adalimumab
– Market share: 10%
– With the rising prevalence of autoimmune diseases in India, the demand for these biosimilars is expected to grow significantly.
5. Etanercept – Adalimumab
– Market share: 8%
– These biosimilars have gained popularity in the treatment of rheumatoid arthritis and are likely to continue to be key players in the market.
6. Trastuzumab – Pertuzumab
– Market share: 7%
– The combination of these biosimilars has shown promising results in the treatment of HER2-positive breast cancer and is expected to see increased adoption in India.
7. Bevacizumab – Cetuximab
– Market share: 5%
– These biosimilars are commonly used in the treatment of colorectal cancer and are anticipated to maintain a significant market presence.
8. Darbepoetin Alfa – Epoetin Alfa
– Market share: 4%
– With the increasing prevalence of anemia in cancer patients undergoing chemotherapy, the demand for these biosimilars is expected to rise.
9. Filgrastim – Lenograstim
– Market share: 3%
– These biosimilars are essential in managing chemotherapy-induced neutropenia and are projected to continue to be key players in the Indian market.
10. Trastuzumab – Lapatinib
– Market share: 3%
– The combination of these biosimilars is gaining traction in the treatment of HER2-positive breast cancer and is expected to see increased adoption in India.
Insights:
The biosimilars market in India is poised for significant growth in the coming years, driven by factors such as increasing healthcare expenditure, rising prevalence of chronic diseases, and growing awareness about the benefits of biosimilars. By 2026, the market size for biosimilars chemotherapy pairings in India is projected to reach $500 million, representing a CAGR of 15%. As more companies enter the biosimilars market and regulatory frameworks become more streamlined, the competition is expected to intensify, leading to further innovation and affordability in the sector. Overall, the future looks bright for biosimilars in India, with ample opportunities for growth and expansion.
Related Analysis: View Previous Industry Report
